PSMA, thus, was identified as the ideal target for radioligand therapy (RLT) with PSMA agents, delivering beta- or alpha-radiation targeted to PCa cells, mainly sparing healthy tissue [4, 5]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.